AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00941863
Drug: Sorafenib 400 mg (200-mg tablet)
RxNorm normalized name: sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet)
Trial: NCT00941863
Drug: Sorafenib 400 mg (Expansion)
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet) expansion
Trial: NCT00386503
Drug: Artesunate + Amodiaquine
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01548703
Drug: BCI-838
RxNorm normalized name: exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BCI-838 100 mg or matching placebo administered once daily for 7 days
Trial: NCT01548703
Drug: BCI-838
RxNorm normalized name: exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BCI-838 or matching placebo administered once daily for 7 days; the dose of BCI-838 will be determined based on the safety and PK data from the preceding dosing arm.
Trial: NCT01217099
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: treatment patients were iv methylprednisolone pulse azithromycin for 5 days.
Trial: NCT02137850
Drug: turoctocog alfa pegol
RxNorm normalized name: Turoctocog alfa pegol
DrugBank: Turoctocog alfa pegol (DB14738)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: For intravenous (i.v.) injection. Frequency and dosage (20-75 U/kg) dependent on whether given as treatment for bleeding episode or as prophylaxis
Trial: NCT00738400
Drug: Vardenafil (Levitra, BAY38-9456)
RxNorm normalized name: vardenafil Oral Tablet [Levitra]
DrugBank: Vardenafil (DB00862)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vardenafil 10 mg tablets daily for 4 weeks, vardenafil 5 mg / 10 mg / 20 mg tablets for consecutive 4 weeks
Trial: NCT01138969
Drug: esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: esomeprazole 20 mg qd for 6 months
Trial: NCT01402843
Drug: pitavastatin, valsartan, placebo
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: pitavastatin 4mg/day 8 week valsartan 320mg/day 8 week
Trial: NCT00949403
Drug: Radio pharmaceuticals C-11 Acetate, and C-11 Palmitate
DrugBank: (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE (DB07955)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection of C-11 Palmitate and C-11 Acetate during PET/CT to determine Liver metabolism
Trial: NCT00823043
Drug: timolol hemihydrate
RxNorm normalized name: Timolol Hemihydrate
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: timolol hemihydrate 0.5% solution
Trial: NCT00823043
Drug: timolol maleate
RxNorm normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: timolol maleate in sorbate
Trial: NCT02651155
Drug: Lubiprostone
RxNorm normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lubiprostone capsules
Trial: NCT01867710
Drug: Abiraterone Acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Type = exact number; unit = mg; number = 1000; form = tablet; route = oral; taken as four 250 mg tablets once daily at least 2 hours after eating and no food should be eaten for at least 1 hour after taking the tablets.
Trial: NCT01867710
Drug: Prednisone 5 mg twice daily
RxNorm normalized name: clindamycin
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: type = exact number; unit = mg; number = 5; form = tablet; route = oral; taken twice daily, the first dose in the morning after a meal and the second dose after a minimum interval of 8 hours in the late afternoon or early evening, after a meal
Trial: NCT01867710
Drug: Prednisone 5 mg once daily
RxNorm normalized name: lisinopril
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: type = exact number; unit = mg; number = 5; form = tablet; route = oral; taken once daily, in the morning after a meal
Trial: NCT01867710
Drug: Prednisone 2.5 mg twice daily
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: type = exact number; unit = mg; number = 2.5; form = tablet; route = oral; taken twice daily, the first dose in the morning after a meal and the second dose after a minimum interval of 8 hours in the late afternoon or early evening, after a meal
Trial: NCT01867710
Drug: Dexamethasone 0.5 mg once daily
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: type = exact number; unit = mg; number = 0.5; form = tablet; route = oral; taken once daily, in the morning after breakfast
Trial: NCT02655510
Drug: F-652
RxNorm normalized name: IL-22 DIMER F-652
DrugBank: Eflepedocokin alfa (DB16366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 10 μg/kg, 30 μg/kg or 45 μg/kg of F-652 on Day 1 and Day 7 via slow intravenous infusion. Three patients will receive 10 μg/kg of F-652. Pharmacokinetic testing will be completed on these subjects. If evaluations demonstrate safety and efficacy signals, the next 3 patients will receive 30 μg/kg. If pharmacokinetic testing demonstrates safety and efficacy signals, the next 3 patients will receive 45 μg/kg.
Trial: NCT03581084
Drug: N-acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Research participants that meet the study inclusion criteria will be admitted to a medical-surgical ward in Moffitt-Long Hospital (UCSF Medical Center) for 6 days and 5 nights and treated with an inhaled mixture of NAC and albuterol four times per day spaced at 4 to 6 hours apart.
Trial: NCT00890708
Drug: Voriconazole (therapeutic drug monitoring)
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dosage adjustment according to trough level of voriconazole in plasma
Trial: NCT03802864
Drug: Liposomal Bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After surgical sperm retrieval, the wound will be injected with liposomal bupivacaine (266 mg) mixed with standard bupivacaine (bupivacaine hydrochloride 50mg) for post-operative pain relief.
Trial: NCT03802864
Drug: Standard Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After surgical sperm retrieval, the wound will be injected only with standard bupivacaine (bupivacaine hydrochloride 100mg) for post-operative pain relief.
Trial: NCT01059630
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion.
Trial: NCT01059630
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion.
Trial: NCT02355821
Drug: Moxonidine
RxNorm normalized name: moxonidine
DrugBank: Moxonidine (DB09242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID Other Names:perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D
Trial: NCT02355821
Drug: Bisoprolol
RxNorm normalized name: Bisoprolol
DrugBank: Bisoprolol (DB00612)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID Other Names: perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D
Trial: NCT02671084
Drug: sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: compare effect of sevoflurane when administered before PCI
Trial: NCT02892019
Drug: Indacaterol acetate 75 μg
RxNorm normalized name: indacaterol
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indacaterol acetate 75 μg o.d. delivered via Concept1 inhaler
Trial: NCT02892019
Drug: Indacaterol acetate 150 μg
DrugBank: Indacaterol (DB05039)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indacaterol acetate 150 μg o.d. delivered via Concept1 inhaler
Trial: NCT03513406
Drug: Sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sugammadex is indicated for the reversal of neuromuscular blockade.
Trial: NCT03513406
Drug: Neostigmine
RxNorm normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neostigmine is indicated for the reversal of neuromuscular blockade.
Trial: NCT03513406
Drug: Glycopyrrolate
RxNorm normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate is used in conjunction with neostigmine to prevent neostigmine's muscarinic effects.
Trial: NCT00109044
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04040309
Drug: Lidocaine injection
RxNorm normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 ml 2 % Lidocaine will be injected into the trigger point in the patient's masseter muscle.
Trial: NCT01663285
Drug: Neoadjuvant Cisplatin and Gemcitabine
RxNorm normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cisplatin 70 mg/m2 through IV for 60 minutes on day 1 of each cycle. Gemcitabine 1,000 mg/m2 IV for 30 minutes on days 1 and 8 during each cycle. Treatment is expected to continue for up to 4 cycles. Chemotherapy will be followed by radical nephroureterectomy within 6 weeks (+/- 2 weeks) from the last date of chemotherapy.
Trial: NCT00226785
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00595985
Drug: sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sorafenib 400mg bid, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
Trial: NCT03631615
Drug: Neoadjuvant chemoradiation plus PD-1 antibody(SHR-1210)
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given the perioperative treatment as below once recruited:~1. induction Neochemotherapy (3w): one cycle of XELOX regimen before surgery;~2. within one week after the induction, concurrent neochemoradiation will be started (5w): intensity modulated radiotherapy was given for tumors and high-risk lymphatic drainage areas.~3. consolidation neochemotherapy will be started in 2-3w after concurrent chemoradiation: one cycle of XELOX regimen; From the beginning of induction chemo to 3w before surgery, PD-1 antibody SHR-1210 will be given q3W.~Re-evaluation will be conducted in 1-3w after consolidation chemo, resectable patients will receive D2 resection.~Adjuvant chemo: We advise starting 4 cycles of XELOX regimen in 4-6w after surgery.
Trial: NCT03116555
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2).
Trial: NCT03116555
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan was used as second line treatment with AGC
Trial: NCT02274870
Drug: Liposome Bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered via local tissue infiltration around the knee joint
Trial: NCT02274870
Drug: Bupivacaine HCl
RxNorm normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered via CFNB
Trial: NCT00971607
Drug: Oxygen + Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxygen with end-tidal MAC of Sevoflurane 0.5 during PCI.
Trial: NCT00971607
Drug: Oxygen (placebo)
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control will receive oxygen only.
Trial: NCT00509834
Drug: hLF1-11
RxNorm normalized name: Human Lactoferrin Peptide hLF1-11
DrugBank: Human Lactoferrin Peptide hLF1-11 (DB16245)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study treatment consists of IV administration of:~(A) hLF1-11 (0.5mg IV bolus daily for 14 days) + fluconazole (up to 1g IV four times daily; 14 days): Group #1, n=10; OR (B) Fluconazole (up to 1g IV four times daily; 14 days) + matching placebo for hLF1-11: Group #2, n=10
Trial: NCT00509834
Drug: hLF1-11
RxNorm normalized name: Human Lactoferrin Peptide hLF1-11
DrugBank: Human Lactoferrin Peptide hLF1-11 (DB16245)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5mg hLF1-11 iv per day for 14 consecutive days
Trial: NCT00325364
Drug: Injectable insulin
RxNorm normalized name: insulin degludec Injectable Solution
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: patient specific dose, injectable, before meals, 24 months
Trial: NCT01486459
Drug: Lithium
RxNorm normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg daily for 6 weeks, increased 250 - 500 mg depending on plasma levels.
Trial: NCT01875380
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03359070
Drug: Dapaconazole
RxNorm normalized name: Dapaconazole
DrugBank: Dapaconazole (DB11985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of 1 gram on the lesion.
Trial: NCT03359070
Drug: Miconazole Nitrate
RxNorm normalized name: Miconazole Nitrate
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Application of 1 gram on the lesion.
Trial: NCT03262857
Drug: use of magnesium sulfate with lidocaine in inferior alveolar nerve block
RxNorm normalized name: lidocaine / magnesium sulfate
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03388749
Drug: Liposomal Annamycin
RxNorm normalized name: Annamycin
DrugBank: Annamycin (DB06420)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
Trial: NCT01161979
Drug: Zonisamide
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Zonisamide capsules 100 mg
Trial: NCT01161979
Drug: Zonegran
RxNorm normalized name: Zonegran
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Zonegran Capsules 100 mg of EISAI INC
Trial: NCT01513733
Drug: tasquinimod
RxNorm normalized name: Tasquinimod
DrugBank: Tasquinimod (DB05861)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tasquinimod 0.25 mg continuously
Trial: NCT00995501
Drug: Dexamethasone Sodium Sulfate
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning
Trial: NCT00995501
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin to maintain blood glucose 80-110 mg/dl.
Trial: NCT01513733
Drug: tasquinimod 0.25 mg; 0.5 mg
DrugBank: Tasquinimod (DB05861)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg continuously, if tolerated
Trial: NCT04590586
Drug: Apremilast
RxNorm normalized name: Apremilast
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Apremilast administered orally as a tablet.
Trial: NCT02007434
Drug: Deoxycholic Acid Injection
RxNorm normalized name: deoxycholic acid Injection
DrugBank: Deoxycholic acid (DB03619)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
Trial: NCT02007434
Drug: Loratadine
RxNorm normalized name: Loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loratadine 10 mg orally from Day -7 until Day 7
Trial: NCT04590586
Drug: Apremilast placebo
RxNorm normalized name: Apremilast
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Matching apremilast placebo administered orally as a tablet.
Trial: NCT04590586
Drug: Lanadelumab
RxNorm normalized name: Lanadelumab
DrugBank: Lanadelumab (DB14597)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Lanadelumab administered as an intravenous (IV) infusion.
Trial: NCT04590586
Drug: Lanadelumab placebo
DrugBank: Lanadelumab (DB14597)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Matching lanadelumab placebo (normal saline) administered as an intravenous (IV) infusion.
Trial: NCT04590586
Drug: Zilucoplan
RxNorm normalized name: Zilucoplan
DrugBank: Zilucoplan (DB15636)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zilucoplan administered as a subcutaneous (sc) injection in the abdomen, thigh, or upper arm.
Trial: NCT04590586
Drug: Zilucoplan placebo
RxNorm normalized name: Zilucoplan
DrugBank: Zilucoplan (DB15636)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching zilucoplan placebo administered as a subcutaneous (sc) injection in the abdomen, thigh, or upper arm.
Trial: NCT01013610
Drug: LNK-754
RxNorm normalized name: MORPHINE SO4 1MG/ML MIN-JET/INT-LNK 10ML
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escalating dose
Trial: NCT03357614
Drug: Sulopenem
RxNorm normalized name: Sulopenem
DrugBank: Sulopenem (DB15284)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy for complicated UTI
Trial: NCT03357614
Drug: Ertapenem
RxNorm normalized name: Ertapenem
DrugBank: Ertapenem (DB00303)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Antibiotic therapy for complicated UTI
Trial: NCT03357614
Drug: Ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy for complicated UTI
Trial: NCT03357614
Drug: Amoxicillin-clavulanate
RxNorm normalized name: amoxicillin-clavulanate
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy for complicated UTI
Trial: NCT02192970
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00929162
Drug: ZD4054 Zibotentan
RxNorm normalized name: Zibotentan
DrugBank: Zibotentan (DB06629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral tablets once daily
Trial: NCT00929162
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 175mg/m2 IV on day 1 every 3 weeks
Trial: NCT00929162
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC of 5.0 IV on day 1 every 3 weeks
Trial: NCT03788538
Drug: dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 minutes before anesthesia induction, all patients were administrated with dexmedetomidine 1 μg/kg/min.At the beginning of induction, dexmedetomidine was changed to corresponding maintenance dose in each group.
Trial: NCT01513733
Drug: tasquinimod 0.25 mg; 0.5 mg; 1.0 mg
DrugBank: Tasquinimod (DB05861)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg for 3 weeks followed by 1.0 mg continuously, if tolerated
Trial: NCT00392899
Drug: UFT adjuvant chemotherapy
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year.
Trial: NCT01893385
Drug: Vitamin D (drug)
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00779194
Drug: Rapamycin
RxNorm normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rapamycin, is given to this group at a starting dose of 2 mg/day.
Trial: NCT00513071
Drug: saracatinib
RxNorm normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02326220
Drug: Alirocumab
RxNorm normalized name: Alirocumab
DrugBank: Alirocumab (DB09302)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03153306
Drug: albumin
RxNorm normalized name: Albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two groups were formed at random for each fluid. In one group, 10ml/kg of 5% albumin was given over 1 hour (the bolus group), and in the other group, the same volume was given over 6 hrs (thecontinuous group)
Trial: NCT02368652
Drug: Candesartan cilexetil 16mg
RxNorm normalized name: CANDESARTAN CILEXETIL 16MG TAB
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily oral administration for 8 weeks
Trial: NCT02368652
Drug: Amlodipine 10mg, Candesartan cilexetil 16mg
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily oral administration for 8 weeks